Table 2 Adherence at 6, 12, and 18 months of follow-up
From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
INF Biosimilar (Inflectra) | INF Bio-originator (Infliximab) | |||
|---|---|---|---|---|
N = 319 | N = 13,119 | |||
Naïve | Prevalent | Naïve | Prevalent | |
Number of patient observed | 96 | 223 | 2,149 | 10,970 |
Total person-days | 19,008 | 45, 019 | 560,142 | 4,692,189 |
6—month adherence, N (%) | ||||
< 50% | 17 (21.79) | 41 (22.78) | 250 (13.55) | 642 (6.18) |
50–80% | 14 (17.95) | 34 (18.89) | 283 (15.34) | 1,207 (11.6) |
> 80% | 47 (60.26) | 105 (58.33) | 1,312 (71.11) | 8,547 (82.21) |
Number of patients during follow-up | 78 (81.25) | 180 (80.72) | 1,845 (85.85) | 10,396 (94.77) |
12—month adherence, N (%) | ||||
< 50% | 27 (40.30) | 61 (41.50) | 485 (30.72) | 1,069 (13.46) |
50–80% | 11 (16.42) | 19 (12.93) | 276 (17.48) | 1,082 (13.62) |
> 80% | 29 (43.28) | 67 (45.58) | 818 (51.80) | 5,793 (72.92) |
Number of patients during follow-up | 67 (69.79) | 147 (65.91) | 1,579 (73.48) | 7,944 (72.42) |
18—month adherence, N (%) | ||||
< 50% | 9 (39.13) | 28 (50.00) | 350 (42.42) | 1,262 (17.06) |
50–80% | 3 (13.04) | 8 (14.29) | 135 (16.36) | 1,381 (18.67) |
> 80% | 11 (47.83) | 20 (35.71) | 340 (41.21) | 4,754 (64.27) |
Number of patients during follow-up | 23 (23.96) | 56 (25.11) | 825 (38.39) | 7,397 (67.43) |